SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00006000
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of solid tumors by stopping blood flow to the tumor. Combining SU5416 with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SU5416 plus irinotecan and cisplatin in treating patients who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
NCT00055835
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy before radiation therapy, and combining chemotherapy with radiation therapy, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of neoadjuvant gemcitabine, paclitaxel, and carboplatin followed by cispl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +91 locations
Conditions: Bladder Cancer, Urethral Cancer
Register for Updates
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00033449
Terminated
This phase I trial is studying the side effects and best dose of gefitinib when given together with radiation therapy with or without cisplatin in treating patients with stage III or stage IV head and neck cancer. Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2013
Locations: University of Colorado, Denver, Colorado
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
Register for Updates
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
NCT00002913
Completed
Phase I trial to study the effectiveness of paclitaxel, cisplatin, and topotecan with or without filgrastim in treating patients who have newly diagnosed stage III or stage IV epithelial ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side e... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
01/23/2013
Locations: Gynecologic Oncology Group of Arizona, Phoenix, Arizona
Conditions: Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Register for Updates
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
NCT00081276
Completed
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This phase II trial is studying how well giving 3-AP together with cisplatin works in treating patients with recurrent or persistent platinum-resistant ovarian epithelial cancer or primary peritoneal cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Register for Updates
Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer
NCT00137358
Withdrawn
Investigator has since decided not to pursue this protocol further. No patients were enrolled. This study is to determine the maximum tolerated dose of external beam radiation to the para-aortic lymph nodes using intensity modulated radiation therapy (IMRT). This protocol will test the hypothesis that the use of IMRT and amifostine will decrease GI toxicity and therefore allow the radiation dose to the para-aortic lymph nodes to be safely escalated.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
01/23/2013
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cervical Cancer
Register for Updates
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
NCT00002772
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which regimen of chemotherapy followed by peripheral stem cell transplantation is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus peripheral stem c... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/22/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00005838
Completed
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. AE-941 may help shrink or slow the growth of non-small cell lung cancer cells. It is not yet known if combination chemotherapy plus radiation therapy is more effective with or without AE-941 for non-small cell lung cancer. This randomized phase III trial is studying com... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2013
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
NCT00977561
Terminated
This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2013
Locations: Pfizer Investigational Site, Washington, District of Columbia +50 locations
Conditions: Small Cell Lung Carcinoma
Register for Updates
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00003358
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of cisplatin plus gemcitabine in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/15/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
NCT00140556
Completed
Radiotherapy (RT) with concurrent chemotherapy represents the state of the art in curative intent treatment for locally advanced squamous carcinoma of the head and neck. Tumor hypoxia and high levels of angiogenesis (blood vessel formation) are associated with treatment failure. Preclinical models reveal that radiotherapy itself may induce tumor secretion of vascular endothelial growth factor (VEGF). Curability may consequently be reduced by multiple mechanisms. Over-expression of epidermal grow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2013
Locations: Department of Radiation Oncology; Duke University Medical Center, Durham, North Carolina
Conditions: Head and Neck Cancer, Pharynx Cancer
Register for Updates
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
NCT00335998
Completed
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. 3-AP may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. 3-AP and cisplatin may make tumor cells more sensitive to radiation therapy. Giving 3-AP and external-beam radiation therapy together with cisplatin may kill m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2013
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Vaginal Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Vulvar Cancer, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
Register for Updates